Effects of dexamethasone and celecoxib on calcium homeostasis and expression of cyclooxygenase-2 mRNA in MG-63 human osteosarcoma cells

Clinical and Experimental Rheumatology

Volumn 24, Issue 4, 2006, Pages 366-372

  Wiontzek, Martin ^a   Matziolis, Georg ^a   Schuchmann, Sebastian ^a   Gaber, Timo ^a   Krocker, Dörte ^a   Duda, George ^a   Burmester, Gerd Rüdiger ^a   Perka, Carsten ^a   Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Celecoxib; Dexamethasone; Inflammation; Intracellular Ca2+ concentration; Osteoblasts

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM ION; CELECOXIB; CYCLOOXYGENASE 2; DEXAMETHASONE; INTERLEUKIN 1BETA; MESSENGER RNA; OSTEOCALCIN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROFLUOROMETRY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ALKALINE PHOSPHATASE; BONE NEOPLASMS; CALCIUM; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DEXAMETHASONE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; OSTEOBLASTS; OSTEOCALCIN; OSTEOSARCOMA; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES;

EID: 33748554474     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. DEEKS JJ, SMITH LA, BRADLEY MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325: 619.
2. CANALIS E, DELANY AM: Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73-81.
3. SHALHOUB V, CONLON D, TASSINARI M et al.: Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes. J Cell Biochem 1992; 50: 425-40.
4. WONG MM, RAO LG, LY H et al.: Long-term effects of physiologic concentrations of dexamethasone on human bone-derived cells. J Bone Miner Res 1990; 5: 803-13.
5. ROSEN GD, BIRKENMEIER TM, RAZ A, HOLTZMAN MJ: Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun 1989; 164: 1358-65.
6. LANGENBACH R, LOFTIN CD, LEE C, TIANO H: Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann N Y Acad Sci 1999; 889: 52-61.
7. KAWAGUCHI H, PILBEAM CC, HARRISON JR, RAISZ LG: The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 1995; 36-46.
8. ZHANG X, MORHAM SG, LANGENBACH R et al.: Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res 2001; 16: 660-70.
9. ZHANG X, SCHWARZ EM, YOUNG DA, PUZAS JE, ROSIER RN, O'KEEFE RJ: Cyclo-oxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405-15.
10. SIMON AM, MANIGRASSO MB, O'CONNOR JP: Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002; 17: 963-76.
11. SCHUCHMANN S, WIONTZEK M, BURMESTER GR, BUTTGEREIT F: Modulation of intracellular calcium signaling and mitochondrial function in cultured osteoblastic cells by dexamethasone and celecoxib during mechanical stimulation. Clin Exp Rheumatol 2004; 22: 184-96.
12. HEREMANS H, BILLIAU A, CASSIMAN JJ, MULIER JC, DE SOMER P: In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines. Oncology 1978; 35: 246-52.
13. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
14. MIN YK, RAO Y, OKADA Y, RAISZ LG, PILBEAM CC: Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells. J Bone Miner Res 1998; 13: 1066-75.
15. HOFBAUER LC, DUNSTAN CR, SPELSBERG TC, RIGGS BL, KHOSLA S: Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998; 250: 776-81.
16. HUGHES FJ, BUTTERY LD, HUKKANEN MV, O'DONNELL A, MACLOUF J, POLAK JM: Cytokine-induced prostaglandin E2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and -independent mechanism in rat osteoblasts in vitro. J Biol Chem 1999; 274: 1776-82.
17. ROSENQUIST JB, OHLIN A, LERNER UH: Cytokine-induced inhibition of bone matrix proteins is not mediated by prostaglandins. Inflamm Res 1996; 45: 457-63.
18. RUTZ HP: Effects of corticosteroid use on treatment of solid tumours. Lancet 2002; 360: 1969-70.
19. CHEUNG R, MITCHELL J: Mechanisms of regulation of G(11)alpha protein by dexamethasone in osteoblastic UMR 106-01 cells. Am J Physiol Endocrinol Metab 2002; 282: E24-E30.
20. GROSCH S, TEGEDER I, NIEDERBERGER E, BRAUTIGAM L, GEISSLINGER G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-4.
21. KUSUNOKI N, YAMAZAKI R, KAWAI S: Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum 2002; 46: 3159-67.
22. CHA HS, AHN KS, JEON CH, KIM J, KOH EM: Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 2004; 24: 207-11.
23. HSUEH SF, LU CY, CHAO CS et al.: Non-steroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation. Brain Res Mol Brain Res 2004; 125: 113-9.
24. EL RAYES BF, ALI S, SARKAR FH PHILIP PA: Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 2004; 3: 1421-6.
25. LIANG L, HU D, LIU W, WILLIAMS JP, OKUNIEFF P, DING I: Celecoxib reduces skin damage after radiation: selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor. Am J Clin Oncol 2003; 26: S114-S121.
26. LEVITT RJ, BUCKLEY J, BLOUIN MJ SCHAUB B, TRICHE TJ, POLLAK M: Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 2004; 316: 421-8.
27. WEI D, WANG L, HE Y, XIONG HQ, ABBRUZZESE JL, XIE K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004; 64: 2030-8.
28. PENNING TD, TALLEY JJ, BERTENSHAW SR et al.: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-lH-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347-65.
29. LISIGNOLI G, TONEGUZZI S, POZZI C et al.: Proinflammatory cytokines and chemokine production and expression by human osteoblasts isolated from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1999; 26: 791-9.
30. FERNANDES JC, MARTEL-PELLETIER J, PELLETIER JP: The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39: 237-46.
31. PARK YG, KANG SK, KIM WJ, LEE YC, KIM CH: Effects of TGF-beta, TNF-alpha, IL-beta and IL-6 alone or in combination, and tyrosine kinase inhibitor on cyclooxygenase expression, prostaglandin E2 production and bone resorption in mouse calvarial bone cells. Int J Biochem Cell Biol 2004; 36: 2270-90.
32. ZINI N, LISIGNOLI G, SOLIMANDO L et al.: IL1-beta and TNF-alpha induce changes in the nuclear polyphosphoinositide signalling system in osteoblasts similar to that occurring in patients with rheumatoid arthritis: an immunochemical and immunocytochemical study. Histochem Cell Biol 2003; 120: 243-50.
33. OLKKU A, BODINE PV, LINNALA-KANKKUNEN A MAHONEN A: Glucocorticoids induce glutamine synthetase expression in human osteoblastic cells: a novel observation in bone. Bone 2004; 34: 320-9.
34. NAMKUNG-MATTHAI H, SEALE JP, BROWN K, MASON RS: Comparative effects of anti-inflammatory corticosteroids in human bone-derived osteoblast-like cells. Ear Respir J 1998; 12: 1327-33.
35. WALSH S, JORDAN GR, JEFFERISS C, STEWART K, BERESFORD, JN: High concentrations of dexamethasone suppress the proliferation but not the differentiation or further maturation of human osteoblast precursors in vitro: relevance to glucocorticoid-induced osteoporosis. Rheumatology (Oxford) 2001; 40: 74-93.
36. YAMAMOTO K, WANG J, YAMAMOTO S, TOBE H: Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid. FEBS Lett 2000; 465: 103-6.
37. INOUE H, UMESONO K, NISHIMORI T, HIRATA Y, TANABE T: Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem Biophys Res Commun 1999; 254: 292-8.
38. MIGITA K, TANAKA H, OKAMOTO K et al.: FK506 augments glucocorticoid-mediated cyclooxygenase-2 down-regulation in human rheumatoid synovial fibroblasts. Lab Invest 2000; 80: 135-41.
39. LASA M, BROOK M, SAKLATVALA J, CLARK AR: Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 2001; 21: 771-80.
40. BRATTSAND R, LINDEN M: Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996; 10 (Suppl. 2): 81-90.
41. GOULDING NJ: The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus. Curr Opin Pharmacol 2004; 4: 629-36.
42. BUTTGEREIT F: Mechanisms and clinical relevance of nongenomic glucocorticoid actions. Z Rheumatol 2000;59 (Suppl. 2): II/119-II/123.
43. 2+ signaling pathway in osteoblasts. Am J Physiol 1998; 274: C1686-C1698.
44. BUTTGEREIT F, STRAUB RH, WEHLING M, BURMESTER GR: Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50: 3408-17.
45. GOODMAN S, MA T, TRINDADE M et al.: COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 2002; 20: 1164-9.
46. CHIKAZU D, LI X, KAWAGUCHI H et al.: Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res 2002; 17: 1430-40.
47. ZHA S, YEGNASUBRAMANIAN V, NELSON WG, ISAACS WB, De MARZO AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004; 215: 1-20.
48. GATELY S, LI WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31: 2-11.
49. KISMET K, AKAY MT, ABBASOGLU O, ERKAN A: Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 2004; 28: 127-42.
50. WANG JL, LIN KL, CHEN JS et al.: Effect of celecoxib on Ca2+ movement and cell proliferation in human osteoblasts. Biochem Pharmacol 2004; 67: 1123-30.
51. 2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 2002; 366: 831-7.